Basel, Switzerland, May 26: ten23 health®, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, today announced changes to its leadership team as part of its ongoing commitment to position the company for further long-term growth. These updates reflect a thoughtful alignment of leadership to support the continued expansion of ten23’s capabilities and manufacturing capacity.
From May 1st, 2026, Andrea Wesp assumed responsibility as Chief Business Officer (CBO). Andrea brings broad experience as a global business leader, having led large international organizations through strategic transformation, innovation and sustainable growth. She combines deep commercial acumen with technical and operational expertise across the pharmaceutical and CDMO value chain. Andrea joins ten23 from Siegfried, where she served as VP Market Development BD & Sales Drug Products. Prior to that, she held a range of roles, including VP New Business Development at Vetter Pharma, and VP Sterile Solutions/BU Pharmaceutical Systems at Schott Pharma. She holds a chemical and process engineering degree from the Technical University of Hamburg, and a business economics degree from FU Hagen in Germany.
Stephanie Knüppel assumed the role of Chief Operating Officer (COO) on April 1st, 2026, after joining ten23 in in June 2025 as Chief of Staff to the COO. She brings extensive experience in leading manufacturing and operations teams, along with strong sterile product knowledge. As E2E Value Stream Lead (Head) of Manufacturing & Packaging Operations at the Roche Kaiseraugst commercial production site, she was responsible for launches, tech transfer and industrialization, and gained extensive experience in compounding, sterile aseptic manufacturing, visual inspection, validation/qualification, device combination products, supply chain resilience, Annex 1 and regulatory authority inspections. Stephanie studied chemistry and holds a PhD from the University of Münster in Germany.
Susanne Jörg, who previously held the position as COO, began her new role as Chief of Staff to the CEO on April 1st, 2026. Before joining ten23 health in 2021 as COO, Susanne held several senior positions in Lonza and Novartis. She has over 15 years’ experience in formulation development, process development, transfer and validation, sterile manufacturing and regulatory submissions for early-, late-stage and life-cycle parenteral dosage forms. As the new Chief of Staff, Susanne will support ten23’s CEO Hanns-Christian Mahler in strategic initiatives, and will be instrumental in preparing the company for its future growth.
From March 1st, 2026, Felicia Werk assumed the role as Chief People & Culture Officer. Felicia joined ten23 in May 2022 to lead ten23’s Learning & Development activities. She previously held a range of senior positions at Bayer, including Global HR Change and Transformation Lead, Head of Business Development, Operational Excellence Manager, Strategy Deployment Lead, and People and Organizational Development Lead. She holds a master’s degree in business psychology from the University of Trier in Germany and an MBA from Heriot-Watt University in the UK.
Alessandra Seriacopi joined ten23 as Chief Quality Officer (CQO) in September 2025. Alessandra brings over 20 years’ experience in quality leadership across the pharmaceuticals, biotech, and vaccines sectors. She was previously Senior Quality Director Drug Product Division EU and APAC at Thermo Fisher Scientific, and held senior roles at MSD, Novartis, and GSK, where she led global quality operations, regulatory compliance, and successful product launches. Alessandra has profound expertise in GMP quality systems, regulatory inspections, and managing complex CDMO environments. She holds a master’s degree in chemistry from the University di Siena in Italy.
The recent appointments are complemented by (in sequence of tenure at ten23) Andrea Allmendinger, Chief Scientific Officer (CSO), Patrick Klassnitz, Chief Finance Officer (CFO), Alissa Monk, Head of Fairstainability, and Creixell Espilla-Gilart, Chief Marketing Officer.
“We are delighted to welcome our newly appointed leaders. Together, they will bring deep and diverse industry expertise, proven execution, and different perspectives that are unique in the CDMO space. The new leadership team will accelerate our next growth stage, support our expansion, and ensure an agile focus on operational excellence and customer needs,” said Hanns-Christian Mahler, Chief Enablement Officer (CEO) at ten23 health.
He continued, “I am confident that this leadership evolution will enhance the way we support and serve our customers and their patients, unlock new opportunities, and build on our strong foundation for continued success and the next stage of growth.”